Comparative Cohort Study of Long-term Safety Outcomes of Risankizumab Compared to Biologic Treatments for Ulcerative Colitis and Crohn’s Disease in a Real-world Setting in Sweden and DenmarkFirst published 01/07/2024 Last updated 03/07/2025 EU PAS number: EUPAS1000000151StudyOngoing